查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672920

PARP 抑制剂市场：按药物类型、应用、分销管道和地区划分

PARP Inhibitor Market, By Drug Type, By Application, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 147 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球 PARP 抑制剂市场规模估计为 78.5 亿美元，预计到 2032 年将达到 143.6 亿美元，2025 年至 2032 年的复合年增长率为 9.0%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 78.5亿美元
效能资料 2020-2024 预测期 2025-2032
预测期：2025 年至 2032 年复合年增长率 9.00％ 2032 年金额预测 143.6亿美元
数字。 2025 年 PARP 抑制剂市场占有率（按地区）
PARP 抑制剂市场-IMG1

聚（ADP-核糖）聚合酵素(PARP) 抑制剂是一种主要用于治疗癌症的标靶治疗。它们透过阻断修復受损 DNA 的 PARP 酶发挥作用，从而帮助化疗和放射线治疗更有效地杀死癌细胞。全球 PARP 抑制剂市场的成长得益于癌症发生率的上升以及 PARP 抑制剂在癌症治疗中的核准和采用的增加。该市场的领先药物包括奥拉帕尼、尼拉帕尼和鲁卡帕尼，这些药物在治疗乳腺癌、卵巢癌和前列腺癌方面已被证实有效。随着对 PARP 抑制剂在新型癌症和联合治疗中的潜力进行研究评估，该市场可能会继续成长。

市场动态

全球 PARP 抑制剂市场的成长得益于全球癌症发病率的不断上升以及 PARP 抑制剂在肿瘤学领域的核准和采用日益增多。根据世界卫生组织统计，2018年癌症病例数和死亡人数分别增加至1,810万人和960万人。持续进行临床试验以评估PARP抑制剂在更广泛患者群体中的疗效以及与其他抗癌治疗的联合使用，可能会推动市场成长。然而，PARP 抑制剂价格高昂、需要进行基因预筛检以选择患者以及实施严格的药物核准监管途径可能会阻碍市场成长。对新应用和新药研发的持续研究可能在不久的将来为市场成长提供新的机会。

研究的主要特点

  • 本报告对全球 PARP 抑制剂市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。
  • 它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
  • 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 全球 PARP 抑制剂市场的主要企业是根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行的分析。
  • 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球 PARP 抑制剂市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过全球 PARP 抑制剂市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 监管情景
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

4. 全球 PARP 抑制剂市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 市场影响

5. 2020-2032 年全球 PARP 抑制剂市场（按药物类型划分）（十亿美元）

  • 介绍
  • 尼拉帕尼
  • 奥拉帕尼
  • 鲁卡帕尼
  • 他拉唑帕尼
  • Veliparib
  • 其他的

6. 全球 PARP 抑制剂市场，按应用划分，2020-2032 年（十亿美元）

  • 介绍
  • 卵巢癌
  • 输卵管癌
  • 乳癌
  • 摄护腺癌
  • 胰臟癌
  • 其他的

7. 2020-2032 年全球 PARP 抑制剂市场按分销管道划分（十亿美元）

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

8. 全球 PARP 抑制剂市场，按地区，2020-2032 年（十亿美元）

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第九章 竞争格局

  • 公司简介
    • AstraZeneca
    • GlaxoSmithKline
    • Merck Co. &Inc
    • AbbVie Inc
    • Clovis Oncology
    • Medivation
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

第 10 章分析师建议

  • 兴衰
  • 一致的机会地图

第 11 章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI3037

Global PARP Inhibitor Market is estimated to be valued at USD 7.85 Bn in 2025 and is expected to reach USD 14.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 7.85 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.00% 2032 Value Projection: USD 14.36 Bn
Figure. PARP Inhibitor Market Share (%), By Region 2025
PARP Inhibitor Market - IMG1

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

  • This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

  • By Drug Type
    • Niraparib
    • Olaparib
    • Rucaparib
    • Talazoparib
    • Veliparib
    • Others
  • By Application
    • Ovarian Cancer
    • Fallopian Tube Cancer
    • Breast Cancer
    • Prostate Cancer
    • Pancreatic Cancer
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • GlaxoSmithKline
    • Merck Co. & Inc
    • AbbVie Inc
    • Clovis Oncology
    • Medivation
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Repare Therapeutics, Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Niraparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Olaparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rucaparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Talazoparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Veliparib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Ovarian Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Fallopian Tube Cancer
    • Mammography
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Breast Cancer
    • Chest X-ray
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Prostate Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pancreatic Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • AstraZeneca
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GlaxoSmithKline
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck Co. & Inc
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AbbVie Inc
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Clovis Oncology
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Medivation
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Johnson & Johnson Services, Inc
    • Pfizer Inc.
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • KaryopharmTherapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact